SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 10.9% – Here’s Why

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shot up 10.9% on Thursday . The stock traded as high as $14.15 and last traded at $14.7180. 1,578,180 shares traded hands during trading, a decline of 81% from the average session volume of 8,470,932 shares. The stock had previously closed at $13.27.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Maxim Group increased their price objective on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, SELLAS Life Sciences Group presently has an average rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Price Performance

The company has a market capitalization of $2.95 billion, a P/E ratio of -65.13 and a beta of 2.42. The firm has a 50-day moving average price of $8.11 and a two-hundred day moving average price of $5.60.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC bought a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at about $26,000. BNP Paribas Financial Markets increased its stake in SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after acquiring an additional 9,299 shares during the period. Concurrent Investment Advisors LLC bought a new position in SELLAS Life Sciences Group during the fourth quarter valued at about $38,000. Beacon Pointe Advisors LLC acquired a new position in SELLAS Life Sciences Group in the 4th quarter valued at approximately $38,000. Finally, California State Teachers Retirement System raised its holdings in SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after acquiring an additional 1,709 shares in the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.